Alkermes cuts staff after Lilly axes pact

Big Pharma's collective stampede from the inhaled insulin field is claiming the jobs of 150 people who work at Alkermes. The developer said it is cutting 18 percent of its staff due to Eli Lilly's decision to follow the example set by Novo Nordisk and Pfizer and pull out of their insulin development program. Alkermes is also closing a manufacturing facility in Chelsea, MA.

"We are implementing a new operational cost structure to align our expenses with near-term revenues, which we anticipate will be lower than expected due to Lilly's termination of the inhaled insulin program," Cambridge, MA-based Alkermes said.

- here's the release
- read the report from Thomson Financial

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.

Takeda’s experimental TAK-620 (maribavir) has hit its main phase 3 goal in helping transplant patients with refractory/resistant cytomegalovirus.

The Chinese vaccine developer committed to starting the late-phase study this month after reviewing data on 150 participants in a phase 1 trial.